{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:14:04Z","timestamp":1767611644007},"reference-count":0,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,19]]},"DOI":"10.7759\/cureus.7049","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T04:58:10Z","timestamp":1582174690000},"source":"Crossref","is-referenced-by-count":6,"title":["The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics"],"prefix":"10.7759","author":[{"given":"Anjali","family":"Patwardhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/19888-the-value-of-intravenous-immunoglobulin-therapy-in-idiopathic-inflammatory-myositis-in-the-current-transformed-era-of-biologics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:21:41Z","timestamp":1707506501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/19888-the-value-of-intravenous-immunoglobulin-therapy-in-idiopathic-inflammatory-myositis-in-the-current-transformed-era-of-biologics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":0,"URL":"https:\/\/doi.org\/10.7759\/cureus.7049","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,19]]}}}